Author name: Dan Hennings

Decision made after reviewing results of interim analysis LONDON – January 7, 2026 – Pulmocide Ltd., (“the Company”), a late-stage […]

LONDON, Jan. 03, 2024 (GLOBE NEWSWIRE) — Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing opelconazole for patients suffering